title: Bevacizumab for corneal neovascularization.
authors.forename: Deborah S
authors.initials: DS
authors.lastname: Jacobs
authors.forename: Mira
authors.initials: M
authors.lastname: Lim
authors.forename: Karen G
authors.initials: KG
authors.lastname: Carrasquillo
authors.forename: Perry
authors.initials: P
authors.lastname: Rosenthal
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab